Thursday, March 21, 2024

Israeli Child Receives Pioneering Seated Proton Therapy with Innovative System

P-Cure is pioneering a groundbreaking approach in the field of proton therapy with its latest achievement: the treatment of a young child diagnosed with ocular cancer using a novel proton therapy system. This innovative system, which has received FDA clearance and is operational at P-Cure's Clinical Development Center in Israel, allows patients to receive treatments in a seated position. This is a significant milestone, as it marks the first time such a method has been used, catering to patients of all ages and regardless of tumor location.

Developed in collaboration with the Hadassah Medical Center, the system utilizes a gantry-less, intensity-modulated particle therapy technology that is both cost-effective and adaptable to existing Linac room configurations. This collaboration has already led to the successful treatment of 14 cancer patients, showcasing the system's ability to improve patient comfort and quality of life, which are crucial for positive clinical outcomes.

The case of 'D', a four-year-old boy, highlights the system's potential to make advanced cancer treatment more accessible. Despite the challenging circumstances, the family opted for treatment in Israel thanks to the availability of P-Cure's system. The technology's adaptive therapy capabilities allow for real-time adjustments based on tumor and healthy tissue dynamics, ensuring precise and safe treatment delivery.

Moreover, P-Cure's system represents a significant advancement in making proton therapy more widely available. Traditional proton therapy solutions require substantial space and investment, limiting their availability. P-Cure's compact and cost-efficient solution can be integrated into existing cancer treatment facilities, potentially transforming the landscape of cancer care by making high-quality proton therapy accessible to a broader patient population.

For parts and services related to Linear Accelerators and more, contact RadParts!

RadParts, a TTG Imaging Solutions Company, is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerators and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost components and support for linear accelerators and radiation equipment. Contact RadParts at 877-704-3838 to learn more.

 

Written by the digital marketing team at Creative Programs & Systems: www.cpsmi.com 

Wednesday, February 21, 2024

Significant Milestone Reached in Compact Particle Accelerator Technology

Researchers, led by The University of Texas at Austin and including international partners and TAU Systems Inc., have made a significant breakthrough in compact accelerator technology by developing a particle accelerator that is under 20 meters long and generates an electron beam with 10 billion electron volts (10 GeV) of energy. This advancement drastically reduces the size of high-energy accelerators, which traditionally span several kilometers. The new compact accelerator opens up potential applications in semiconductor testing, medical imaging and therapy, and scientific research.

The team's technology, an advanced wakefield laser accelerator, utilizes a powerful laser to create plasma waves in helium gas, propelling electrons to high energies. A novel approach involving nanoparticles significantly enhances the efficiency of this process. The researchers aim to apply this technology in various fields, including testing the radiation resistance of space electronics, examining the internal structures of semiconductor chips, developing new cancer treatments, and capturing atomic-scale dynamics with X-ray free electron lasers.

This compact accelerator's design is based on a concept first described in 1979, with recent advancements making it more powerful and practical for broader use. The team envisions future iterations of the accelerator that are even more compact, powered by table-top lasers capable of firing thousands of times per second. This development represents a major leap in making high-energy particle acceleration more accessible and versatile for research and industry.

To learn more, visit the original article posted in phys.org/news

_________________

RadParts, a TTG Imaging Solutions Company, is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerators and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost components and support for linear accelerators and radiation equipment. Contact RadParts at 877-704-3838 to learn more.

 

Written by the digital marketing team at Creative Programs & Systems: www.cpsmi.com 

Wednesday, January 24, 2024

Innovative Radiotherapy Method Potentially Halves Treatment Duration for Head and Neck Cancer

A groundbreaking study by the IAEA has found that a new radiotherapy technique for head and neck cancer could significantly shorten treatment times, especially beneficial for low- and middle-income countries (LMICs). This research, the largest of its kind, involved 12 centers across ten LMICs, including Argentina, Brazil, Cuba, India, Indonesia, Pakistan, Philippines, South Africa, Thailand, and Uruguay. The study showed that administering fewer but higher doses of radiation has similar clinical outcomes to standard treatments, potentially halving treatment durations.

This advancement could be a game-changer for LMICs, where head and neck cancer is particularly prevalent, accounting for 76% of global cases and 84% of deaths in 2020. Shorter treatment times mean reduced waitlists, allowing more patients to receive prompt care. This is crucial in LMICs, where challenges like increased demand for radiotherapy, limited resources, and centralized healthcare services in major cities contribute to long waiting periods. Reducing these wait times not only eases patient and family anxiety but also improves survival chances. The findings have been published in the International Journal of Radiation Oncology, Biology, and Physics and align with global initiatives like the IAEA's Rays of Hope, which aims to bolster cancer treatment capabilities in these countries.

What is Radiation Therapy?

The IAEA's HYPNO trial, launched in 2010, has introduced a transformative approach to radiotherapy for head and neck cancer, a disease prevalent in low- and middle-income countries (LMICs). Traditional treatment typically spans seven weeks, but prior studies have explored more intense regimens, either increasing the dose over the same period or maintaining the dose but shortening the duration to five to six weeks. These methods proved safe and effective.

Expanding on these findings, the IAEA's latest research tested an even more intensive method: hypofractionated radiotherapy. This approach administers fewer but higher radiation doses over just four weeks, roughly half the time of standard treatment. In a groundbreaking comparison involving 729 patients, the outcomes and survival rates for those receiving accelerated normo-fractionated and hypofractionated radiotherapy were similar, affirming the latter's efficacy and safety in a shorter timeframe.

The trial's influential results, presented by Professor Søren M. Bentzen at the American Society for Therapeutic Radiology and Oncology's annual meeting, underscore the need for randomized controlled trials in LMICs to establish evidence-based practices. This research exemplifies how international collaboration and the IAEA's role in connecting global cancer centers can lead to significant advancements in radiation oncology. The HYPNO trial's success means that radiation oncologists can now treat more patients effectively and efficiently, offering a practical solution to resource limitations in cancer care.

May Abdel-Wahab, Director of the IAEA Division of Human Health, highlighted the trial's significance in demonstrating the value of funded, multinational research tailored to global cancer needs. This innovation in cancer care, supported by IAEA's initiatives like Rays of Hope Anchor Centres, is crucial in ensuring that patients worldwide receive timely and high-quality treatment.

__________

For high-quality, user-friendly, low-cost parts support for linear accelerators and radiation equipment, contact RadParts.

RadParts, a TTG Imaging Solutions Company, is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerators and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost components and support for linear accelerators and radiation equipment. Contact RadParts at 877-704-3838 to learn more.

 

Written by the digital marketing team at Creative Programs & Systems: www.cpsmi.com